Givinostat (ITF2357)

Givinostat (ITF2357)は一種の有効なHDAC阻害剤で、トウモロコシHD2、HD1BとHD1Aに作用して、無細胞試験でIC50値が10 nM、7.5 nMと16 nMそれぞれに分かれます。臨床2期。

価格 在庫  
USD 214 あり
USD 403 あり
USD 403 あり
USD 1222 あり

Givinostat (ITF2357) 化学構造
分子量: 475.97

高品質保証

カスタマーフィードバック(3)

MSDS

製品説明

  • Compare HDAC Inhibitors
    HDAC製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 Givinostat (ITF2357)は一種の有効なHDAC阻害剤で、トウモロコシHD2、HD1BとHD1Aに作用して、無細胞試験でIC50値が10 nM、7.5 nMと16 nMそれぞれに分かれます。臨床2期。
ターゲット HDAC
IC50 7.5 to 16 nM [1]
In vitro試験 In LPS-stimulated cultured human peripheral blood mononuclear cells (PBMCs), ITF2357 reduces the release of TNFα, IL-1α, IL-1β, and IFNγ, with IC50 of 10-25 nM, respectively. Using the combination of IL-12 plus IL-18, ITF2357 reduces IFNγ and IL-6 production with IC50 of 12.5-25 nM, independent of decreased IL-1 or TNFα. [1] ITF2357 is cytotoxic in multiple myeloma (MM) cell lines (RPMI8226, NCI-H929, JJN3, KMS 11, KMS 12, KMS 18, and KMS 20) and acute myelogenous leukemia (AML) cell lines (HL-60, THP-1, U937, KASUMI, KG-1, and TF-1), with IC50 of 200 nM. ITF2357 activates the intrinsic apoptotic pathway, upregulates p21 and downmodulates Bcl-2 and Mcl-1. ITF2357 inhibits the production of IL-6, VEGF, and IFNγ in mesenchymal stromal cells (MSCs) by 80-95%. [2] ITF2357 favors β-cell survival during inflammatory conditions. ITF2357 at concentrations of 25 and 250 nM increases islet cell viability, enhances insulin secretion, inhibits release of MIP-1α and MIP-2, reduces NO production and decreases apoptosis rates. [3]
In vivo試験 ITF2357 (1-10 mg/kg) reduces LPS-induced serum TNFα and IFNγ by more than 50% in mice. Anti-CD3-induced cytokines are not suppressed by ITF2357 in PBMCs in the circulation in mice. In concanavalin-A-induced hepatitis, ITF2357 (1 or 5 mg/kg) significantly reduces liver damage. [1] ITF2357 (10 mg/kg) significantly prolongs survival of severe combined immunodeficient mice inoculated with the AML-PS in vivo passaged cell line. [2] In a mouse model of closed head injury (CHI), ITF2357 (10 mg/kg) improves neurobehavioral recovery, decreases neuronal degeneration, reduces lesion volume, and induces glial apoptosis. [4]
臨床試験 A Phase II clinical trial of ITF2357 in active systemic onset juvenile idiopathic arthritis (SOJIA) has been completed.
特集 An orally active, potent inhibitor of histone deacetylases (HDACs).

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

Enzymatic Assay for HDAC Inhibitory Activity of Synthetic Compounds The assay is performed by adding 100 μL substrate (2×105 cpm), 40 μL buffer (50 mM Tris-HCl, pH 8.0, 750 mM NaCl, 5 mM PMSF, 50% glycerol) and 95 μL distilled water to the crude cellular extract (5 μL). ITF2357 (50 μL) is added to test for HDAC inhibition. The mixture is incubated overnight at room temperature and the reaction quenched by adding 50 μL of a solution containing 259 μL 37% HCl and 28 μL acetic acid in 1 mL distilled water. The [3H]acetyl residues released from the substrate are separated by organic extraction with 600 μL of ethyl acetate, 200 μL of the organic phase is added to standard scintillation fluid, and radioactivity is measured by a beta-counter. Inhibition of HDACs is expressed as the concentration inhibiting 50% of the control activity (by comparing the radioactivity of the samples containing inhibitors to that of the control containing cellular crude extract alone).

細胞アッセイ: [1]

細胞株 peripheral blood mononuclear cells (PBMCs)
濃度 1 nM - 1 μM
反応時間 24 hours
実験の流れ After washing, the isolated PBMCs are resuspended in RPMI containing 5% FCS at 5×106/mL, added to a 50-mL conical polypropylene tube, and placed at 4 °C overnight. The PBMCs are resuspended the next morning and added to a 96-well flat microtiter plate (100 μL per well). ITF2357 is then added for inhibition studies, and the plates are incubated at 37 °C for 1 hour, after which the cells are stimulated with LPS or other stimulants in a final volume of 200 μL per well. The supernatants are removed after incubation at 37 °C for 24 hours, and frozen at -80 °C until assayed for cytokines.

動物実験: [1]

動物モデル Mice. For LPS induction of serum cytokines: BALB/c; for anti-CD3-induced cytokines: CD1; for concanavalin A (Con A)-induced acute hepatitis: BALB/c or C57Bl6.
製剤 Dissolved in water
投薬量 0.01-50 mg/kg
投与方法 By gavage in 100 μL water.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Givinostat (ITF2357) SDF
分子量 475.97
化学式

C24H27N3O4.HCl.H2O

CAS No. 732302-99-7
保管 3年-20℃
2年-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 95 mg/mL (199.59 mM)
Ethanol 3 mg/mL (6.3 mM)
Water <1 mg/mL
In vivo 30% propylene glycol, 5% Tween 80, 65% D5W 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (6-((diethylamino)methyl)naphthalen-2-yl)methyl 4-(hydroxycarbamoyl)phenylcarbamate hydrochloride hydrate

文献中の引用 (8)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related HDAC 阻害剤

  • LMK-235

    LMK-235は一種のHDAC4とHDAC5選択性阻害剤で、IC50値が11.9 nM と 4.2 nMに分かれます。

  • CAY10603

    CAY10603は一種の有効的で、選択性的なHDAC6阻害剤で、IC50値が2 pMになって、HDAC6に作用する選択性はHDACsに作用する選択性より200倍以上が高くなります。

  • 4SC-202

    4SC-202は一種の選択性I型HDAC阻害剤で、HDAC1、HDAC2とHDAC3に作用する時のIC50値が1.20 μM、1.12 μMと0.57 μMそれぞれに分かれて、Lysine specific demethylase 1 (LSD1)にも抑制活性を表します。臨床1期。

  • HPOB

    HPOBは一種の有効的で、選択性HDAC6阻害剤で、IC50値が56 nMになって、HDAC6に作用する選択性は他のHDACsに作用する選択性より30倍以上が高くなります。

  • Panobinostat (LBH589)

    Panobinostat (LBH589) は一種の新たで、広範なHDAC阻害剤で、無細胞試験でIC50値が5 nMです。臨床3期。

  • Vorinostat (SAHA, MK0683)

    Vorinostat (suberoylanilide hydroxamic acid, SAHA)は一種のHDAC阻害剤で、無細胞試験でIC50値が約10 nMです。

  • Entinostat (MS-275)

    Entinostat (MS-275)はHDAC1とHDAC3を強く抑制して、無細胞試験でIC50値が0.51μMと1.7μMに分かれて、抑制作用がHDACs 4/6/8/10より良くなリます。臨床3期。

  • Trichostatin A (TSA)

    Trichostatin A (TSA)は一種のHDAC阻害剤で、無細胞試験でIC50値が1.8 nM程度です。

  • Romidepsin (FK228, Depsipeptide)

    Romidepsin (FK228, Depsipeptide)は一種の有効なHDAC1とHDAC2阻害剤で、無細胞試験でIC50値が36 nMと47 nMに分かれます。

    Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.

  • RGFP966

    RGFP966は一種のHDAC3阻害剤で、無細胞試験でIC50値が0.08μMになって、HDAC3に作用する選択性が他のHDACに作用する選択性より200倍以上高くなります。

最近チェックしたアイテム

Tags: Givinostat (ITF2357)を買う | Givinostat (ITF2357)供給者 | Givinostat (ITF2357)を購入する | Givinostat (ITF2357)費用 | Givinostat (ITF2357)生産者 | オーダーGivinostat (ITF2357) | Givinostat (ITF2357)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ